Vivus (VVUS +2.1%) shares gyrate wildly after an FDA advisory panel votes to require...

|By:, SA News Editor

Vivus (VVUS +2.1%) shares gyrate wildly after an FDA advisory panel votes to require cardiovascular outcomes trials for drugs without a theoretical risk or signal for cardiovascular harm. The vote could be seen as a negative for weight-loss drug companies such as VVUS, OREX -2% and ARNA +5.3%, who now may have to run additional tests to convince the FDA of a drug's safety.